ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

ClinicalTrials.gov ID: NCT04929028

Public ClinicalTrials.gov record NCT04929028. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Risk-Adapted Therapy for HIV-Associated Anal Cancer

Study identification

NCT ID
NCT04929028
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
40 participants

Conditions and interventions

Interventions

  • Anoscopy Procedure
  • Biospecimen Collection Procedure
  • Capecitabine Drug
  • Colonoscopy Procedure
  • Computed Tomography Procedure
  • Digital Rectal Examination Procedure
  • Echocardiography Test Procedure
  • Fludeoxyglucose F-18 Other
  • Fluorouracil Drug
  • Intensity-Modulated Radiation Therapy Radiation
  • Lymph Node Biopsy Procedure
  • Magnetic Resonance Imaging Procedure
  • Mitomycin Drug
  • Nivolumab Biological
  • Positron Emission Tomography Procedure
  • Proctoscopy Procedure
  • Questionnaire Administration Other
  • Sigmoidoscopy Procedure

Procedure · Drug · Other + 2 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 8, 2022
Primary completion
Sep 14, 2031
Completion
Sep 14, 2031
Last update posted
Apr 12, 2026

2022 – 2031

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Zuckerberg San Francisco General Hospital San Francisco California 94110
George Washington University Medical Center Washington D.C. District of Columbia 20037
Moffitt Cancer Center Tampa Florida 33612
University of Illinois Chicago Illinois 60612
Washington University School of Medicine St Louis Missouri 63110
Mount Sinai West New York New York 10019
Icahn School of Medicine at Mount Sinai New York New York 10029
Mount Sinai Hospital New York New York 10029
Montefiore Medical Center-Einstein Campus The Bronx New York 10461
Montefiore Medical Center - Moses Campus The Bronx New York 10467
Pennsylvania Hospital Philadelphia Pennsylvania 19107
Lyndon Baines Johnson General Hospital Houston Texas 77026-1967
M D Anderson Cancer Center Houston Texas 77030
Virginia Mason Medical Center Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04929028, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04929028 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →